238 related articles for article (PubMed ID: 30037803)
1. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; de Witte T; Neukirchen J; Sekeres MA; Brunner AM; Roboz GJ; Steensma DP; Bhatt VR; Platzbecker U; Cluzeau T; Prata PH; Itzykson R; Fenaux P; Fathi AT; Smith A; Germing U; Ritchie EK; Verma V; Nazha A; Maciejewski JP; Podoltsev NA; Prebet T; Santini V; Gore SD; Komrokji RS; Zeidan AM
Blood Adv; 2018 Jul; 2(14):1765-1772. PubMed ID: 30037803
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Sloand EM; Olnes MJ; Shenoy A; Weinstein B; Boss C; Loeliger K; Wu CO; More K; Barrett AJ; Scheinberg P; Young NS
J Clin Oncol; 2010 Dec; 28(35):5166-73. PubMed ID: 21041705
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-thymocyte globulin-based immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent non-severe aplastic anaemia: a retrospective study from a single centre.
Shen Y; Li Y; Liu Q; Liu W; Yu Q; Hu H; Liu S; Dong J; Xu M; Hong Y; Chen Y; Deng S; Zhuang H; Hu Z; Lin S; Shen Y; Shen J; Zhou Y; Ye B; Wu D
Ann Med; 2023; 55(2):2271475. PubMed ID: 37871262
[TBL] [Abstract][Full Text] [Related]
8. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes.
Hata T; Tsushima H; Baba M; Imaizumi Y; Taguchi J; Imanishi D; Nagai K; Tomonaga M; Miyazaki Y
Int J Hematol; 2013 Dec; 98(6):687-93. PubMed ID: 24254637
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia.
Chang MH; Kim KH; Kim HS; Jun HJ; Kim DH; Jang JH; Kim K; Jung CW
Eur J Haematol; 2010 Feb; 84(2):154-9. PubMed ID: 19912311
[TBL] [Abstract][Full Text] [Related]
11. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
12. Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia.
Zhang X; Li Z; Geng W; Song B; Wan C
Yonsei Med J; 2018 Jul; 59(5):643-651. PubMed ID: 29869462
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.
Fattizzo B; Ireland R; Dunlop A; Yallop D; Kassam S; Large J; Gandhi S; Muus P; Manogaran C; Sanchez K; Consonni D; Barcellini W; Mufti GJ; Marsh JCW; Kulasekararaj AG
Leukemia; 2021 Nov; 35(11):3223-3231. PubMed ID: 33664463
[TBL] [Abstract][Full Text] [Related]
14. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
Kadia TM; Borthakur G; Garcia-Manero G; Faderl S; Jabbour E; Estrov Z; York S; Huang X; Pierce S; Brandt M; Koller C; Kantarjian HM; Ravandi F
Br J Haematol; 2012 May; 157(3):312-20. PubMed ID: 22360602
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study.
Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Ann Hematol; 2013 Jun; 92(6):817-24. PubMed ID: 23318980
[TBL] [Abstract][Full Text] [Related]
16. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Nam JM; Robyn J; Loberiza F; Maciejewski JP; Simonis T; Molldrem J; Young NS; Barrett AJ
Blood; 2002 Sep; 100(5):1570-4. PubMed ID: 12176872
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
19. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
20. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis.
Wei J; Huang Z; Guo J; Zhang Y; Wang C; Zhu X; Zhang Y
Ann Hematol; 2015 Jun; 94(6):955-62. PubMed ID: 25666078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
